Minnesota Medical Development's Rebound HRD:
This article was originally published in Clinica
The Rebound HRD hernia repair device developed by Minnesota Medical Development has been granted 510(k) clearance by the US FDA. The Rebound HRD is a self-expanding surgical mesh device composed of Nitinol, designed for the laparoscopic repair and/or reinforcement of both inguinal and ventral hernias. It conforms to the anatomy while providing stability, eliminating the need for anchoring, which, in turn, minimises patient post-op discomfort and the risk of nerve/blood vessel injury. It can also be used for other soft tissue defects where weakness exists and where the support of a non-absorbable material is preferred. The Plymouth, Minnesota company CE-marked the product for sale in the EU in June (see Clinica No 1261, p 22).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.